10-Q: TELA Bio Reports Strong Revenue Growth, Reduced Q2 Loss

TELA Bio, Inc. announced significant revenue growth and a narrower net loss for the second quarter of 2025, driven by new customer additions and product launches, despite continued overall losses.

Summary

• Revenue for the three months ended June 30, 2025, increased by 26% to $20.2 million, up from $16.1 million in the prior year period.
• Net loss for the second quarter decreased by 21% to $9.9 million, compared to $12.6 million in the same period last year.
• Gross profit for the quarter rose by 27% to $14.1 million, with gross margin improving to 70% from 69%.
• For the six months ended June 30, 2025, revenue increased by 18% to $38.7 million, up from $32.7 million.
• Net loss for the six months ended June 30, 2025, increased by 16% to $21.2 million, compared to $18.3 million in the prior year, primarily due to a $7.6 million gain on the sale of a product line in Q1 2024.
• Cash and cash equivalents stood at $35.0 million as of June 30, 2025, down from $52.7 million at December 31, 2024.
• The accumulated deficit reached $379.9 million as of June 30, 2025.
• The company launched OviTex IHR in the U.S. in April 2024 and in Europe in June 2025, and larger sizes of OviTex PRS in March 2025.
• Unit sales volume for OviTex increased by 17% in Q2 2025, and OviTex PRS unit sales increased by 40% in Q2 2025.

Sentiment

Score: 6

Explanation: The company demonstrates strong revenue growth and improved gross margins, indicating positive operational momentum. However, it continues to incur significant net losses and burn cash, leading to a substantial accumulated deficit. While liquidity is stated as sufficient for the next 12 months, the need for potential future capital raises and exposure to macroeconomic risks temper the overall sentiment. The appointment of a new President is a positive management development.

Positives

• Strong revenue growth of 26% for the three months ended June 30, 2025, and 18% for the six months ended June 30, 2025, driven by new customers and international sales.
• Improved net loss for the three months ended June 30, 2025, decreasing by 21% to $9.9 million.
• Gross margin increased to 70% for the three months ended June 30, 2025, from 69% in the prior year, due to a lower charge for excess and obsolete inventory as a percentage of revenue.
• Significant increase in unit sales volume for both OviTex (17%) and OviTex PRS (40%) in the second quarter of 2025.
• Successful launch of new product configurations, including OviTex IHR in Europe and larger OviTex PRS sizes in the U.S.
• Reduced cash used in operating activities for the six months ended June 30, 2025, at $17.6 million, compared to $25.1 million in the prior year period.
• Extension of monthly interest payments on the MidCap term loan by an additional 12 months, followed by 12 months of straight-line amortization, pushing the principal payment closer to maturity in May 2027.

Negatives

• Continued net losses since inception, with an accumulated deficit of $379.9 million as of June 30, 2025.
• Net loss for the six months ended June 30, 2025, increased by 16% to $21.2 million, primarily due to the absence of the $7.6 million gain from the NIVIS product line sale recognized in the prior year period.
• Cash and cash equivalents decreased significantly to $35.0 million as of June 30, 2025, from $52.7 million at December 31, 2024.
• Working capital decreased to $41.7 million as of June 30, 2025, from $62.5 million at December 31, 2024.
• Average selling prices for hernia products decreased due to product mix, with an increased share of smaller-sized units.

Risks

• Uncertainty of product development and commercial acceptance of developed products.
• Impact of macroeconomic conditions, including general economic slowdown or recession, inflationary pressures, banking instability, monetary policy changes, and changes in trade policies (tariffs).
• Geopolitical factors such as the ongoing Russia-Ukraine conflict, conflicts in the Middle East, and increasing tensions between China and Taiwan.
• External cybersecurity events impacting or disrupting normal hospital operations, potentially reducing procedural volumes.
• Disruptions to the supply of critical surgical and hospital supplies, leading to deferrals of elective surgical procedures.
• Financial strain on hospital customers, potentially affecting demand, reimbursement rates, and new product adoption.
• Ability to expand, manage, and maintain the direct sales and marketing organization.
• Performance of Aroa Biosurgery Ltd. as the exclusive contract manufacturer for OviTex and OviTex PRS products.
• Ability to achieve and maintain adequate levels of coverage or reimbursement for current and future products.
• Competition from larger competitors in a highly competitive industry.
• Ability to obtain additional capital to finance planned operations, with no assurance of favorable terms or availability, and potential for stockholder dilution or restrictive debt covenants.
• Volatility of capital markets and other adverse macroeconomic factors impacting stock price and cost of capital.
• Need to maintain minimum net revenue levels as per the MidCap Credit Agreement, with default leading to increased interest rates.
• Potential for adverse safety events, restrictions on use, or product liability claims related to products.

Future Outlook

The company anticipates incurring additional losses for the foreseeable future as it continues to invest in sales and marketing initiatives to support growth in existing and new markets, and in additional research and development activities. It expects sales and marketing expenses to decrease as a percentage of revenue as revenue grows, and general and administrative expenses to decrease as a percentage of revenue as growth initiatives are efficiently executed. Research and development expenses as a percentage of revenue are expected to vary based on new product development and clinical trial initiatives. The company believes its existing cash resources will be sufficient to meet capital requirements, debt repayment obligations, and fund operations for at least the next 12 months from the issuance of this report. It is currently evaluating the impact of the One Big Beautiful, Bill Act (OBBBA) on its consolidated financial statements.

Management Comments

• We are a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patients own anatomy.
• Our growing product portfolio is purposefully designed to leverage the patients natural healing response while minimizing long-term exposure to permanent synthetic materials.
• We are committed to delivering our advanced technologies with a strong economic value proposition to assist surgeons and institutions in providing next-generation soft-tissue repair solutions to more patients worldwide.
• We believe that genuine collaboration with surgeons and healthcare providers results in the development of new solutions that empower patient care and addresses unmet needs within the soft tissue reconstruction market.
• We expect to incur losses for the foreseeable future.

Industry Context

The company operates in the highly competitive soft-tissue reconstruction market, focusing on hernia repair and plastic/reconstructive surgery. Its strategy involves combining biologic matrices and polymer materials to optimize clinical outcomes and offer cost-effective solutions. The industry faces challenges from macroeconomic conditions, including inflationary pressures, supply chain disruptions, and financial strain on hospital customers, as well as the impact of cybersecurity events on procedural volumes. The company's focus on clinical data publication (BRAVO, BRAVO II, OPERA studies) and strategic partnerships (LiquiFix distribution, NIVIS sale) reflects a broader industry trend towards evidence-based medicine and diversified commercialization strategies. The continued investment in R&D for new product variations and enhancements aligns with the industry's drive for innovation and addressing unmet needs.

Comparison to Industry Standards

• The BRAVO study's 24-month recurrence rate of 2.6% for ventral hernias using OviTex provides a clinical benchmark for product effectiveness, particularly given that 78% of enrolled patients were high-risk for surgical site occurrences (SSOs).
• The OviTex PRS portfolio is supported by non-human primate data demonstrating more rapid tissue integration and remodeling compared to the market-leading biologic matrix in its indication, suggesting a competitive advantage in performance.
• The company's revenue sharing arrangement with Aroa Biosurgery Ltd., where it pays 27% of net sales for OviTex and OviTex PRS products (with specific terms for OviTex IHR), allows for competitive pricing and cost-savings to customers, which is a unique supply chain model compared to traditional direct manufacturing costs.
• The estimated annual U.S. total addressable market for OviTex products is approximately $1.8 billion, and for OviTex PRS products is approximately $800 million, indicating significant market opportunities within the soft-tissue reconstruction sector.
• The company's contracting with three national group purchasing organizations (GPOs) in the U.S. for OviTex and OviTex PRS products is a standard industry practice to increase market access and hospital penetration.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently subject to any material legal proceedings.

Stakeholder Impact

• **Shareholders**: Experience dilution risk from potential future equity raises. Benefit from strong revenue growth and improved gross margins, but face ongoing losses and cash burn. The new officer liability limitation may reduce corporate risk.
• **Employees**: Benefit from continued investment in R&D and sales infrastructure, indicating job stability and growth opportunities. New equity incentive plan shares provide potential for increased stock-based compensation.
• **Customers (Hospitals/Surgical Facilities)**: Benefit from new product launches (OviTex IHR, larger OviTex PRS sizes) and continued R&D, offering more advanced soft-tissue reconstruction solutions. May face potential price increases due to tariffs.
• **Suppliers (Aroa Biosurgery Ltd.)**: Continue to be a key partner with a revenue-sharing agreement, benefiting from increased product demand. Share the cost of U.S. tariffs on imports from New Zealand.
• **Creditors (MidCap Financial Trust)**: The extension of interest-only payments on the term loan provides the company with more operational flexibility, but the debt remains a significant liability with specific covenants.

Next Steps

• Continue to enroll patients for the BRAVO II study, evaluating OviTex in robot-assisted ventral and inguinal hernia repairs.
• Continue to enroll patients in the OPERA study, evaluating the safety profile of OviTex PRS in pre-pectoral and sub-pectoral implant-based breast reconstructions.
• Evaluate and finalize the clinical study protocol and anticipate additional FDA interactions to support a pre-market application for OviTex PRS for use in breast reconstruction.
• Assess additional strategic partnerships with medical device companies for distribution, product development, and/or licensing agreements for complementary or related products.
• Continue to contract with additional Group Purchasing Organizations (GPOs) and other Integrated Delivery Networks (IDNs) to increase access and penetration of hospital accounts.
• Devote research and development resources to develop additional variations of OviTex and OviTex PRS products, including longer-acting resorbable polymers and packaging enhancements.
• Explore the development of lower-cost, higher-margin resorbable polymer-based devices targeting current indications.
• Explore additional technologies that may complement existing products or expand the product portfolio within the hernia, plastic and reconstruction, and broader soft-tissue reconstruction market.
• Continue to make investments in research and development efforts to develop improvements and enhancements to the product portfolio.
• Assess the impact of the One Big Beautiful, Bill Act (OBBBA) on consolidated financial statements.

Key Dates

Recommendation

TELA Bio demonstrates robust revenue growth and operational improvements, including a narrower net loss in Q2 and improved gross margin. The company's product pipeline and market expansion efforts are positive indicators. However, it continues to operate at a net loss with a substantial accumulated deficit and declining cash reserves, necessitating potential future capital raises. While management asserts sufficient liquidity for the next 12 months, the macroeconomic risks and competitive landscape warrant a cautious approach. The stock is a 'hold' for investors seeking growth in the medical technology sector, but who should monitor profitability trends, cash burn, and capital structure closely.

Keywords

Medical Technology, Soft-Tissue Reconstruction, Hernia Repair, Abdominal Wall Reconstruction, Plastic Surgery, OviTex, OviTex PRS, Biologic Matrices, Polymer Materials, Surgical Devices, FDA Clearance, SEC Filing, 10-Q, Financial Results, Medical Devices